{
  "content": "G. Hindricks et al.\n\n2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC\nEur Heart J (2021)\n\nP. Kirchhof et al.\n\nEarly rhythm-control therapy in patients with atrial fibrillation\nN Engl J Med (2020)\n\nD. Kim et al.\n\nTreatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study\nBMJ (2021)\n\nP. Zimetbaum\n\nAntiarrhythmic drug therapy for atrial fibrillation\nCirculation (2012)\n\nL.S. Wann et al.",
  "source": "https://www.sciencedirect.com/science/article/abs/pii/S0149291825002176",
  "chunk_id": "37939b55-fe77-4e94-b361-2e4d10730705",
  "similarity_score": 0.37116914987564087,
  "query": "atrial fibrillation guidelines ESC AHA CCS amiodarone beta-blockers recommendations clinical practice first-line therapy",
  "rank": 20,
  "title": "Cost-Effectiveness of Antiarrhythmic Drugs for Treating Paroxysmal or Persistent Atrial Fibrillation in China: An Economic Evaluation",
  "authors": "Fuming Li, Dunming Xiao, Yu Xia, Junling Weng, Shimeng Liu, Yingyao Chen",
  "year": "2025",
  "journal": "Clinical Therapeutics",
  "reference": "Li, F., Xiao, D., Xia, Y., Weng, J., Liu, S., & Chen, Y. (2025). Cost-effectiveness of antiarrhythmic drugs for treating paroxysmal or persistent atrial fibrillation in China: An economic evaluation. Clinical Therapeutics. https://doi.org/Not available",
  "doi": "Not available",
  "chunk_index": 23,
  "total_chunks": 30,
  "retrieved_at": "2025-07-24T21:58:06.270513"
}